

**OSTEOCIS 3 mg
kit for radiopharmaceutical preparation**

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

OSTEOCIS 3 mg kit for radiopharmaceutical preparation

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 3 mg of sodium oxidronate.

The radionuclide is not part of the kit.

Excipient with known effect:

Each vial contains 4.5 mg of sodium.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Kit for radiopharmaceutical preparation.

White powder.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

This medicinal product is for diagnostic use only.

After radiolabelling with sodium pertechnetate (^{99m}Tc) solution, the solution obtained may be used for bone scintigraphy, where it delineates areas of altered osteogenesis.

4.2 Posology and method of administration

This medicinal product is intended for use in designated nuclear medicine facilities only, and should only be handled by authorised personnel.

Posology

Adults and elderly population

The average activity administered by single intravenous injection is 500 MBq (300-700 MBq) on a patient of average weight (70 kg). Other activities may be justifiable.

Renal impairment

Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients.

Patients with high bone uptake and/or severe renal impairment, a dose adjustment can be required (see sections 4.4 and 11).

Paediatric population

The use in children and adolescents has to be considered carefully, based upon clinical needs and assessing the risk/benefit ratio in this patient group.

The activities to be administered to children and to adolescents may be calculated according to the recommendations of the Paediatric Task Group of the EANM (2008). This activity can be calculated from the formula below using a multiplying coefficient based on the patient's body mass (table 1).

$$\text{Recommended activity [MBq]} = 35 \text{ MBq} \times \text{Factor (Table 1)}$$

Table 1

Body weight	factor	Body weight	factor	Body weight	factor
3 kg	= 1*	22 kg	= 5.29	42 kg	= 9.14
4 kg	= 1.14*	24 kg	= 5.71	44 kg	= 9.57
6 kg	= 1.71	26 kg	= 6.14	46 kg	= 10.00
8 kg	= 2.14	28 kg	= 6.43	48 kg	= 10.29
10 kg	= 2.71	30 kg	= 6.86	50 kg	= 10.71
12 kg	= 3.14	32 kg	= 7.29	52-54 kg	= 11.29
14 kg	= 3.57	34 kg	= 7.72	56-58 kg	= 12.00
16 kg	= 4.00	36 kg	= 8.00	60-62 kg	= 12.71
18 kg	= 4.43	38 kg	= 8.43	64-66 kg	= 13.43
20 kg	= 4.86	40 kg	= 8.86	68 kg	= 14.00

*In very young children (up to 1 year) a minimum dose of 40 MBq is necessary in order to obtain images of sufficient quality.

Method of administration:

This medicinal product should be reconstituted before administration to the patient.

The radiolabelled solution is administered by a single intravenous injection.

For instructions on extemporaneous preparation of the medicinal product before administration, see section 12.

For patient preparation, see section 4.4.

Image acquisition

Images obtained shortly after injection (e.g. in the so-called "3-phase bone scan" procedure) will only partly reflect metabolic bone activity. Late phase static scintigraphy should be performed not earlier than 2 hours after injection. The patient should void before scanning.

4.3 Contraindications

Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or to any of the components of the labeled radiopharmaceutical.

4.4 Special warnings and precautions for use

Potential for hypersensitivity or anaphylactic reactions

If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately and intravenous treatment initiated, if necessary. To enable immediate action in emergencies, the necessary medicinal products and equipment such as endotracheal tube and ventilator must be immediately available.

Individual benefit/risk justification

For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required diagnostic information.

Renal impairment

Careful consideration of the benefit risk ratio in these patients is required since an increased radiation exposure is possible (see section 11).

In patients with high bone uptake and/or severe renal impairment, careful consideration of the indication is required since an increased exposure is possible in these patients. This must be taken into account when calculating the activity to be administered (see section 11).

Paediatric population

In infants and children particular attention should be paid to the relatively higher radiation exposure of the epiphyses in growing bone.

For information on the use in paediatric population, see section 4.2.

Careful consideration of the indications is required since the effective dose per MBq is higher than in adults (see section 11)

Patient preparation

The patient should be well-hydrated before the start of the examination and urged to void before scanning and as often as possible during the first hours after the study in order to reduce radiation to the bladder wall.

To avoid accumulation of tracer in the musculature it is advised that strenuous exercise must be avoided immediately after injection until satisfactory bone imaging has been effected.

Inadvertent or accidental subcutaneous administration of technetium (^{99m}Tc) oxidronate should be avoided as perivascular inflammation has been described.

Specific warnings

This medicinal product contains 4.5 mg of sodium per vial. Depending on the time when you administer the injection, the content of sodium given to the patient may in some cases be greater than 1 mmol (23 mg) per dose. This should be taken into account in patients in low sodium diet.

Precautions with respect to environmental hazard are in section 6.6.

4.5 Interaction with other medicinal products and other forms of interaction

The accumulation of technetium (^{99m}Tc) oxidronate in the skeleton, and thus the quality of the scintigraphic procedure, may be decreased after medication with:

- chelates,
- diphosphonates,
- after tetracycline or
- after iron containing drugs.

Regular medication with aluminium containing drugs (notably antacids) may lead to abnormal high accumulation of technetium (^{99m}Tc) in the liver, presumably caused by formation of labelled colloids.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

When an administration of radiopharmaceuticals to a woman of childbearing potential is intended, it is important to determine whether or not she is pregnant. Any woman who has missed a period should be assumed to be pregnant until proven otherwise. If in doubt about her potential pregnancy (if the woman has missed a period, if the period is very irregular, etc.), alternative techniques not using ionising radiation (if there any) should be offered to the patient.

Pregnancy

Radionuclide procedures carried out on pregnant women also involve radiation doses to the foetus. Only imperative investigations should therefore be carried out during pregnancy, when the likely benefit exceeds the risk incurred by mother and foetus.

Administration of 700 MBq technetium (^{99m}Tc) oxidronate to a patient with normal bone uptake results in an absorbed dose to the uterus of 4.41 mGy. The dose decreases to 2.03 mGy in patients with high bone uptake and/or severely impaired kidney function. Doses above 0.5 mGy would be regarded as a potential risk for the foetus.

Breastfeeding

Before administering a radioactive medicinal product to a mother who is breastfeeding, consideration should be given to the possibility of delaying the administration until the mother has ceased breastfeeding and to what is the most appropriate choice of radiopharmaceuticals, bearing in mind the secretion of activity in breast milk. If the administration is considered necessary, one breast feed should be banked prior to injection and the subsequent one discarded after injection. Breast feeding can be restarted 4 hours post injection.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8 Undesirable effects

The following table presents how the frequencies are reflected in this section:

Very common	($\geq 1/10$)
Common	($\geq 1/100$ to $< 1/10$)
Uncommon	($\geq 1/1,000$ to $< 1/100$)
Rare	($\geq 1/10,000$ to $< 1/1,000$)
Very rare	($< 1/10,000$)
Not known	(cannot be estimated from the available data)

In this table, the undesirable effects are classified in accordance with the MedDRA SOCs.

MedDRA Body system SOCs	Preferred term	Frequency
Immune system disorders	Anaphylactoid reaction	Very rare
Vascular disorders	Hypotension	
Gastro-intestinal disorders	Nausea	
Skin and subcutaneous tissue disorders	Rash	
Musculoskeletal and connective tissue disorders	Arthralgia	

Adverse drug effects are extremely rare following administration of technetium (^{99m}Tc) oxidronate injection. Reports suggest an incidence of not more than one in 200 000 administrations. Symptoms of anaphylactoid reactions are rash, nausea, hypotension and sometimes arthralgia. Onset of symptoms may be delayed 4 to 24 hours after administration.

Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. As the effective dose is 4.0 mSv when the maximal recommended activity of 700 MBq is administered these adverse events are expected to occur with a low probability.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Finland

www-sivusto: www.fimea.fi

Lääkealan turvallisuus- ja kehittämiskeskus Fimea

Lääkkeiden haittavaikutusrekisteri

PL 55

00034 FIMEA

4.9 Overdose

In the event of the administration of a radiation overdose with technetium (^{99m}Tc) oxidronate the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by forced diuresis and bladder voiding.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Radiopharmaceutical for diagnostic use
ATC code: V09BA01

At the chemical concentrations used for diagnostic examinations, technetium (^{99m}Tc) oxidronate does not appear to exert any pharmacodynamic activity.

5.2 Pharmacokinetic properties

Distribution

Intravenously administered technetium (^{99m}Tc) oxidronate is rapidly distributed throughout the extracellular space.

Organ uptake

Skeletal uptake begins almost immediately and proceeds rapidly. 30 minutes post injection 10% of the initial dose is still present in whole blood. At 1 hour, 2 hours, 3 hours and 4 hours after injection these values are resp. 5%, 3%, 1.5% and 1%.

Elimination

Clearance from the body takes place via the kidneys. Of the administered activity about 30% is cleared within the first hour, 48% within two hours and 60% within 6 hours.

5.3 Preclinical safety data

Minimal liver abnormalities are seen at the level of 30 mg/kg in rats.

In subacute toxicity studies rats do not react to the administration of 10 mg/kg/day for 14 days, dogs show histological changes in the liver (microgranuloma) after 3 and 10 mg/kg/day for 14 days. In dogs, treated for 14 consecutive days, long-lasting indurations at the site of injection were observed.

This agent is not intended for regular or continuous administration.

Reproduction, mutagenicity studies and long-term carcinogenicity studies have not been carried out.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Stannous chloride dihydrate
Ascorbic acid
Sodium chloride
Sodium hydroxide (for pH adjustment)
Under nitrogen atmosphere

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 12.

6.3 Shelf life

1 year.
The expiry date is indicated on the outer packaging and on each vial.

Do not store the radiolabelled product above 25°C and use within 8 hours after labelling.

6.4 Special precautions for storage

Store the kit at 2°C – 8°C (in a refrigerator).

For storage conditions of the reconstituted medicinal product, see section 6.3.
Storage of radiopharmaceuticals should be in accordance with national regulations for radioactive materials.

6.5 Nature and contents of container

15 ml, colourless, European Pharmacopoeia type I, drawn glass vials, closed with chlorobutyl rubber stoppers and aluminium capsules.

Packsize: 5 multidose vials.

6.6 Special precautions for disposal and other handling

General warnings

Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation.

Radiopharmaceuticals should be prepared by the user in a manner which satisfies both radiation safety and pharmaceutical quality requirements. Appropriate aseptic precautions should be taken.

Content of the vial is intended only for use in the preparation of technetium (^{99m}Tc) oxidronate and is not administered directly without first undergoing the preparative procedure.

For instructions on extemporaneous preparation of the medicinal product before administration, see section 12.

If at any time in the preparation of this product the integrity of this vial is compromised, it should not be used.

Administration procedures should be carried out in a way to minimize risk of contamination of the medicinal product and irradiation of the operators. Adequate shielding is mandatory.

The content of the kit before extemporary preparation is not radioactive. However, after sodium pertechnetate (^{99m}Tc) injection is added, adequate shielding of the final preparation must be maintained.

The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spills of urine, vomiting, etc. Radiation protection precautions in accordance with national regulations must therefore be taken.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

CIS bio international
BP 32 - 91192 Gif sur Yvette Cedex RANSKA

8. MARKETING AUTHORISATION NUMBER

Finland : 11251

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Finland : 29.11.1993 /

10. DATE OF REVISION OF THE TEXT

10/2016

11. DOSIMETRY

Technetium (^{99m}Tc) is produced by means of a ($^{99}\text{Mo}/^{99m}\text{Tc}$) generator and decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.02 hours to technetium (^{99}Tc) which, in view of its long half-life of 2.13×10^5 years can be regarded as quasi stable.

The dosimetry data were quoted from ICRP publications 53 and 80 for phosphonates.

Organ absorbed doses and effective doses for normal bone uptake were recalculated in Publication 80.

Radiation exposure (normal bone uptake)– ICRP 80

Organ	Absorbed dose per unit activity administered (mGy/MBq)				
	Adult	Children (age in years)			
		15	10	5	1
Adrenals	0.0021	0.0027	0.0039	0.0058	0.011
Bladder	0.048	0.060	0.088	0.073	0.13
Bone surfaces	0.063	0.082	0.13	0.22	0.53
Brain	0.0017	0.0021	0.0028	0.0043	0.0061
Breast	0.00071	0.00089	0.0014	0.0022	0.0042
Gall bladder	0.0014	0.0019	0.0035	0.0042	0.0067
GI-tract					
Stomach	0.0012	0.0015	0.0025	0.0035	0.0066
Small intestine	0.0023	0.0029	0.0044	0.0053	0.0095
Colon	0.0027	0.0034	0.0053	0.0061	0.011
Upper large intestine	0.0019	0.0024	0.0039	0.0051	0.0089
Lower large intestine	0.0038	0.0047	0.0072	0.0075	0.013
Heart	0.0012	0.0016	0.0023	0.0034	0.0060
Kidneys	0.0073	0.0088	0.012	0.018	0.032
Liver	0.0012	0.0016	0.0025	0.0036	0.0066
Lungs	0.0013	0.0016	0.0024	0.0036	0.0068
Muscles	0.0019	0.0023	0.0034	0.0044	0.0079
Oesophagus	0.0010	0.0013	0.0019	0.0030	0.0053
Ovaries	0.0036	0.0046	0.0066	0.0070	0.012
Pancreas	0.0016	0.0020	0.0031	0.0045	0.0082
Red marrow	0.0092	0.010	0.017	0.033	0.067
Skin	0.0010	0.0013	0.0020	0.0029	0.0055
Spleen	0.0014	0.0018	0.0028	0.0045	0.0079
Testes	0.0024	0.0033	0.0055	0.0058	0.011
Thymus	0.0010	0.0013	0.0019	0.0030	0.0053
Thyroid	0.0013	0.0016	0.0023	0.0035	0.0056
Uterus	0.0063	0.0076	0.012	0.011	0.018
Remaining organs	0.0019	0.0023	0.0034	0.0045	0.0079
Effective dose (mSv/MBq)	0.0057	0.0070	0.011	0.014	0.027

The effective dose resulting from the administration of an activity of 700 MBq of technetium (^{99m}Tc)-oxidronate for an adult weighing 70 kg is about 4.0 mSv.

For an administered activity of 700 MBq the typical radiation dose to the target organ (bone) is 44.1 mGy and the typical radiation dose to the critical organ (bladder wall) is 33.6 mGy.

Radiation exposure (high bone uptake and/or severely impaired kidney function) – ICRP 53

Organ	Absorbed dose per unit activity administered (mGy/MBq)				
	Adult	Children (age in years)			
		15	10	5	1
Adrenals	0.0035	0.0050	0.0072	0.011	0.021
Bladder wall	0.0025	0.0035	0.0054	0.0074	0.015
Bone surface	0.12	0.16	0.26	0.43	1.0
Breast	0.0021	0.0021	0.0032	0.0051	0.0096
Stomach wall	0.0026	0.0032	0.0051	0.0073	0.014
Small intestine	0.0031	0.0038	0.0057	0.0085	0.016
Upper large intestine	0.0029	0.0036	0.0053	0.0086	0.015
Lower large intestine	0.0034	0.0042	0.0065	0.0096	0.018
Kidneys	0.0030	0.0037	0.0056	0.0087	0.016
Liver	0.0027	0.0033	0.0049	0.0075	0.014
Lungs	0.0030	0.0037	0.0053	0.0081	0.015
Ovaries	0.0029	0.0041	0.0059	0.0089	0.016
Pancreas	0.0032	0.0040	0.0059	0.0089	0.016
Red marrow	0.018	0.023	0.037	0.072	0.14
Spleen	0.0026	0.0034	0.0051	0.0078	0.015
Testes	0.0023	0.0027	0.0039	0.0060	0.011
Thyroid	0.0024	0.0037	0.0054	0.0083	0.014
Uterus	0.0029	0.0037	0.0054	0.0082	0.015
Other tissue	0.0030	0.0036	0.0053	0.0081	0.015
Effective dose equivalent (mSv/MBq)	0.0082	0.011	0.017	0.028	0.061

In cases of high bone uptake and/or severely impaired kidney function, the effective dose equivalent resulting from an administered activity of 700 MBq of technetium (^{99m}Tc) oxidronate is 5.74 mSv. The typical radiation dose to the target organ (bone) is 84 mGy and the typical radiation dose to the critical organ (red marrow) is 12.6 mGy.

12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

Withdrawals should be performed under aseptic conditions. The vials must never be opened. The solutions should be withdrawn via the stopper using a single dose syringe fitted with suitable protective shielding and a disposable sterile needle or using an authorised automated application system.

If the integrity of this vial is compromised, the product should not be used.

The product contains no antimicrobial preservative.

- Method of preparation

Sodium pertechnetate (^{99m}Tc) injection should comply with European Pharmacopoeia specifications.

Take a vial from the kit and put it in an appropriate lead shielding.

Using a hypodermic syringe, introduce through the rubber stopper 2 to 10 mL of sterile and pyrogen-free sodium pertechnetate (^{99m}Tc) injection, radioactivity varying as a function of the volume from 0.75 to maximum 11 GBq.

Do not use a breather needle as the contents are under nitrogen: after introduction of the volume of sodium pertechnetate (^{99m}Tc) injection, without removing the needle, withdraw an equivalent volume of nitrogen in order to avoid excess pressure in the vial.

Shake for about 2 minutes and allow resting for 15 minutes at room temperature.

The obtained preparation is a clear and colourless solution, with a pH ranging between 5.0 and 7.0.

The vial should never be opened and must be kept inside its lead shielding. The solution should be removed aseptically through the stopper with a sterile lead protected syringe.

- **Quality control**

Limpidity of the solution after preparation, pH, radioactivity and gamma spectrum should be checked before use.

Radiochemical purity

The quality of labelling (radiochemical purity) should be checked according to the following procedure.

Method

Paper chromatography

Materials and reagents

1. Adsorbent
2. Whatman 17 Chr paper strips (A and B) for paper chromatography. Trace a starting line 2.5 cm from one of the ends of each strip.
2. Solvents

Solvent A : 0.9% sodium chloride solution
Solvent B : methanol-water (85/15 V/V)
3. Small developing tanks
2 appropriate glass tanks (A and B). Keep the containers stoppered before use.
4. Miscellaneous
Forceps, scissors, syringes, needles, appropriate counting apparatus.

Procedure

Do not let air enter the vial to be tested and store all vials containing radioactive solution in lead shieldings.

1. Introduce respectively in tanks A and B a layer of 2 cm of solvents A and B.
2. Apply a drop of the preparation to the starting line of strip A using a syringe and needle. Apply another drop of the preparation to the starting line of strip B. Note the time.
3. Using forceps, introduce each strip vertically into the corresponding developing tank (i.e. container with solvent A for strip A and container with solvent B for strip B), with the starting line downward. Stopper the containers.
4. When the solvent has reached the top of the strips, use the forceps to remove each strip and allow to dry in the air.
5. After identifying the strips, cut strip A at $R_f = 0.15$ and strip B at $R_f = 0.4$.

6. Separately count each section of the strips and record the obtained values (use an appropriate detection apparatus with a constant counting time, and known geometry and background noise).

7. Calculations

Correct the counting data for background noise.

Calculate the percentage of hydrolysed technetium (^{99m}Tc) from counting data for the A strip :

$$\% \text{ hydrolysed } ^{99m}\text{Tc} = \frac{\text{activity of strip A for Rf 0.0-0.15}}{\text{total activity of strip A}} \times 100$$

Calculate the percentage of free technetium (^{99m}Tc) from counting data for the B strip:

$$\% \text{ free } ^{99m}\text{Tc} = \frac{\text{activity of strip B for Rf 0.4-1.0}}{\text{total activity of strip B}} \times 100$$

Calculate the percentage of bound technetium (^{99m}Tc) (radiochemical purity):

$$\% \text{ bound } ^{99m}\text{Tc} = 100\% - (\% \text{ hydrolysed } ^{99m}\text{Tc} + \% \text{ free } ^{99m}\text{Tc})$$

8. The percentage of bound ^{99m}Tc (radiochemical purity) should be more than 95 % and the percentage of total hydrolysed ^{99m}Tc and free ^{99m}Tc should be less than 5 %.

Any unused product or waste material should be disposed of in accordance with local requirements.

Finland:

Detailed information on this medicinal product is available on the website of FIMEA: www.fimea.fi kotisivuilta.